#ICYMI: Last week, we disclosed 3 new pre-clinical pipeline programs in #geneticdisease and solid tumors at our New Program & Platform Event. For full details on these programs and how the Dynamo™ platform led to these discoveries, access the webcast recording at the link below. https://lnkd.in/g79n8BnA
Relay Therapeutics’ Post
More Relevant Posts
-
New #JITC article: Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial https://bit.ly/3wharIS
-
-
NRG1+ tumors may have a higher rate of metastasis at the time of diagnosis compared with KRAS+ tumors. Visit FindTheFusions.com and find out more about the metastatic potential of NRG1+ tumors. #PrecisionOncology #FindTheFusions #PrecisionMedicine https://bit.ly/3X41Jse
-
-
Customer success, clinical training, and sales support specialist with a proven track record of transforming patient outcomes, driving sales, educating, and supporting clinicians of all levels.
Come learn about Embolization Evolved at SIR. Hope to see you there!
TriSalus is excited to see Educational Programs showcasing clinical data on our unique platform approach for #liver and #pancreatic tumors at #SIR2024! Join these presentations to learn more.
-
-
NRG1+ tumors are associated with aggressive features and poor outcomes. Find out more about the threat of NRG1+ tumors at FindTheFusions.com #PrecisionOncology #FindTheFusions #PrecisionMedicine
-
-
🌟 🌟 Welcome to read the #HighlyCitedPaper "Numerical Investigation on the Anti-Angiogenic Therapy-Induced Normalization in Solid Tumors" Paper link: https://lnkd.in/gisRFvZs
-
-
💫 #ONCOnews 💫 🌟 Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial 👉 The results suggest that [89Zr]Zr-girentuximab PET–CT has a favourable safety profile and is a highly accurate, non-invasive imaging modality for the detection and characterisation of clear-cell renal cell carcinoma, which has the potential to be practice changing. 🔗 https://buff.ly/47pElIX #OncEd #OncoAlert
-
-
This article outlines the proposed definitions for the T categories for the ninth edition TNM stage classification of thymic malignancies in the 9th edition of the IASLC's Thymic Epithelial Tumor Staging Project. https://bit.ly/3rxuEYx #LCSM
-
-
This study reanalyzes epidermal growth factor receptor 2 (ERBB2) data from a previous study to characterize patient subgroups with ERBB2-low tumors. https://ja.ma/3XwqugE
-
-
We’re investigating a #Nectin4 targeted antibody-drug conjugate (ADC) in patients with advanced or metastatic #UrothelialCarcinoma or other solid tumors. Learn more about the Phase 1 trial here: https://e.lilly/3VR2ns8
Head of R&D, Vice President at Suven Pharmaceuticals Limited
3moGreat opportunity!